Lipocine Inc. (NASDAQ: LPCN) will present and meet investors at the H.C. Wainwright conference on September 16, 2026. Investors can access the presentation through a live webcast and later replay in the Events section of Lipocine’s website, giving them scheduled online access to management’s conference presentation.
Key Highlights
- The conference will take place in person and virtually from September 14 to September 16, 2026.
- Lipocine’s webcast and replay will be available through the Events section of its website.
- The development pipeline includes LPCN 1154, LPCN 2201, LPCN 2101, LPCN 2203, LPCN 2401, LPCN 1148 and LPCN 1107.
Lipocine (NASDAQ: LPCN) Sets September 16 Conference
Presentation Management will present during the conference, which runs from September 14 through September 16, 2026. Lipocine (NASDAQ: LPCN) said investors seeking one-on-one meetings should contact an H.C. Wainwright representative. Lipocine describes itself as a biopharmaceutical company developing oral therapeutics through its proprietary technology platform. Its pipeline includes LPCN 1154 for postpartum depression, LPCN 2201 for major depressive disorder, LPCN 2101 for epilepsy and LPCN 2203 for essential tremor.
Webcast Access Extends Beyond The Live Event
The webcast will be archived for a stated period following the live event. Investors can also arrange individual meetings through the conference representative. Lipocine said TLANDO, its oral testosterone undecanoate prodrug, is approved by the FDA for conditions linked to endogenous testosterone deficiency in adult males.
FAQs
Q: When will Lipocine present at the H.C. Wainwright conference?
A: Lipocine Inc. is scheduled to present on September 16, 2026, at the H.C. Wainwright conference in New York. The event will be available in person and virtually.
Q: How can investors watch Lipocine’s conference presentation?
A: Investors can watch a live webcast and access a later replay through Lipocine’s website Events section. One-on-one meetings can be arranged through an H.C. Wainwright representative.
Q: Which Lipocine drug candidates are in development?
A: Lipocine’s pipeline includes LPCN 1154 for postpartum depression and LPCN 2201 for major depressive disorder. It also lists candidates targeting epilepsy, essential tremor and obesity management.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.